RU93053992A - METHOD FOR CLEANING AND STORING FACTOR IX, WATER SOLUTION OF PURIFIED FACTOR IX, COMPOSITION CONTAINING FACTOR IX, METHOD OF TREATMENT - Google Patents

METHOD FOR CLEANING AND STORING FACTOR IX, WATER SOLUTION OF PURIFIED FACTOR IX, COMPOSITION CONTAINING FACTOR IX, METHOD OF TREATMENT

Info

Publication number
RU93053992A
RU93053992A RU93053992/14A RU93053992A RU93053992A RU 93053992 A RU93053992 A RU 93053992A RU 93053992/14 A RU93053992/14 A RU 93053992/14A RU 93053992 A RU93053992 A RU 93053992A RU 93053992 A RU93053992 A RU 93053992A
Authority
RU
Russia
Prior art keywords
factor
purified
cleaning
treatment
composition containing
Prior art date
Application number
RU93053992/14A
Other languages
Russian (ru)
Other versions
RU2142806C1 (en
Inventor
С. Хуанг Чин
Энкодзи Такаси
Хо Лаура
Р. Клежински Ричард
Л. Уикс Ричард
Фельдман Фред
Original Assignee
Рон-Пуленк Рорер Интернэшнл (Хоулдингз) Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рон-Пуленк Рорер Интернэшнл (Хоулдингз) Инк. filed Critical Рон-Пуленк Рорер Интернэшнл (Хоулдингз) Инк.
Priority claimed from PCT/US1992/001600 external-priority patent/WO1992015324A1/en
Publication of RU93053992A publication Critical patent/RU93053992A/en
Application granted granted Critical
Publication of RU2142806C1 publication Critical patent/RU2142806C1/en

Links

Claims (1)

Предложен новый способ защиты фактора свертывания крови IX от протеаз во время очистки или хранения. Высокие концентрации одной или более растворимых в воде органических и неорганических солей использованы для стабилизации фактора IX, содержащегося в растворах, получаемых из плазмы крови, или в растворах, получаемых из других источников, против его превращения в клинически непригодные белковые структуры, такие, как фактор IXа и/или вырожденные белки фактора IX. Способ полезен для стабилизации препаратов фактора IX с промежуточной чистотой во время очистки и для сохранения целостности очищенного фактора IX при длительном хранении. Кроме того, также раскрыты стабильные препараты фактора IX, обладающие большой удельной активностью.A new method is proposed for protecting blood coagulation factor IX from proteases during purification or storage. High concentrations of one or more water soluble organic and inorganic salts are used to stabilize factor IX contained in solutions obtained from blood plasma, or in solutions obtained from other sources, against its conversion into clinically unsuitable protein structures, such as factor IX a and / or degenerate proteins factor IX. The method is useful for stabilizing factor IX preparations with intermediate purity during purification and for maintaining the integrity of purified factor IX during long-term storage. In addition, stable factor IX preparations having high specific activity are also disclosed.
RU93053992A 1991-03-01 1992-02-26 Method of purification and storage of, aqueous solution of purified factor ix, composition containing factor ix, and method of treatment RU2142806C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66292791A 1991-03-01 1991-03-01
US662,927 1991-03-01
US662927 1991-03-01
PCT/US1992/001600 WO1992015324A1 (en) 1991-03-01 1992-02-26 Preparation of factor ix

Publications (2)

Publication Number Publication Date
RU93053992A true RU93053992A (en) 1996-10-10
RU2142806C1 RU2142806C1 (en) 1999-12-20

Family

ID=24659784

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93053992A RU2142806C1 (en) 1991-03-01 1992-02-26 Method of purification and storage of, aqueous solution of purified factor ix, composition containing factor ix, and method of treatment

Country Status (17)

Country Link
US (3) US6063909A (en)
EP (1) EP0573605B1 (en)
JP (1) JP3418621B2 (en)
AT (1) ATE195877T1 (en)
AU (1) AU671586B2 (en)
BR (1) BR9205700A (en)
CA (1) CA2105282C (en)
DE (1) DE69231401T2 (en)
DK (1) DK0573605T3 (en)
ES (1) ES2150914T3 (en)
FI (1) FI114969B (en)
GR (1) GR3034946T3 (en)
MX (1) MX9200882A (en)
NO (1) NO315856B1 (en)
RU (1) RU2142806C1 (en)
SG (1) SG48282A1 (en)
WO (1) WO1992015324A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573605T3 (en) * 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Preparation of Factor IX
WO1994005692A1 (en) * 1992-08-27 1994-03-17 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE19506633A1 (en) * 1995-02-25 1996-08-29 Octapharma Ag Process for the preparation of factor IX from biological sources
WO1998018957A1 (en) * 1996-10-31 1998-05-07 Roche Diagnostics Gmbh METHOD FOR DETERMINING THE CATALYTIC ACTIVITY OF FACTOR IXa
WO2002040544A2 (en) * 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20050008580A1 (en) * 2003-04-09 2005-01-13 Wyeth Hemophilia treatment by inhalation of coagulation factors
WO2006017263A1 (en) 2004-07-12 2006-02-16 Taro Pharmaceutical Industries Ltd. Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US7560445B2 (en) * 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
WO2011086197A1 (en) 2010-01-18 2011-07-21 Novo Nordisk Health Care Ag Purification of blood coagulation factors
JP5876868B2 (en) * 2010-03-30 2016-03-02 オクタファルマ・アーゲー Method for purifying vitamin K-dependent protein such as IX coagulation factor
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (en) * 1980-07-22 1982-11-25 Immuno Ag METHOD FOR PRODUCING A NEW HUMAN PROTEIN-BASED PREPARATION PROCESSING BLOOD
DE3045153A1 (en) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg METHOD FOR THE PRODUCTION OF BLOOD COagulation FACTORS AND THE PREPARATION OF FACTORS IX AND X THEREFORE PRODUCED
DE3101752A1 (en) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "METHOD FOR PURIFYING THE BLOOD COAGINING FACTORS II, VII, IX AND / OR X AND PREPARATIONS PRODUCED THEREFORE"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
ATE36457T1 (en) * 1983-05-02 1988-09-15 Immuno Ag METHOD OF INACTIVATING REPRODUCTIVE pathogens.
JPS60132912A (en) * 1983-12-21 1985-07-16 Kao Corp Shampoo composition
ATE74164T1 (en) * 1985-04-22 1992-04-15 Genetics Inst MANUFACTURING WITH HIGH PERFORMANCE OF ACTIVE FACTOR IX.
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (en) 1986-06-23 1989-05-12 Transgene Sa VECTORS FOR INTEGRATION INTO EUKARYOTIC CELLS PROVIDING EXPRESSION OF FACTOR IX, CELULLAR LINES OBTAINED AND PROCESS FOR THEIR PREPARATION
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
DE3877529T2 (en) 1987-10-23 1996-11-07 Centre Regional De Transfusion Production of highly purified human factor IX and other plasma protein concentrate and its therapeutic use.
JPH01258700A (en) 1988-04-05 1989-10-16 Green Cross Corp:The Purification of blood coagulation ix factor
DE3826792C1 (en) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (en) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (en) * 1991-01-25 1997-03-25 Immuno Ag COMPLEX CONTAINING THE coagulation factor IX
DK0573605T3 (en) * 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Preparation of Factor IX

Similar Documents

Publication Publication Date Title
RU93053992A (en) METHOD FOR CLEANING AND STORING FACTOR IX, WATER SOLUTION OF PURIFIED FACTOR IX, COMPOSITION CONTAINING FACTOR IX, METHOD OF TREATMENT
DE69029765D1 (en) Stabilization of highly purified proteins
NO933114L (en) PREPARATION OF FACTOR IX
DE69111205D1 (en) Stabilization of pharmaceutical compounds containing calcitonin.
ATE65401T1 (en) STABLE, INJECTABLE SOLUTIONS OF SALTS OF VINCRISTIN.
DK248886D0 (en) SPIRO-IMIDAZOLIDINE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
NO2006006I1 (en) Activated Protein C
RU2001111373A (en) COMPOSITION OF PERFLUOROUS CARBIDE SUBSTITUTE BASED ON PERFUORORGANIC COMPOUNDS EMULSION FOR MEDICAL AND BIOLOGICAL PURPOSES
JPS57128635A (en) Pharmaceutical preparation of gamma-globulin for venoclysis
ATE135364T1 (en) ANHYDROUS CRYSTALS OF 4-CARBAMOYL-1-BETA-D-RIBOFURANOSYL-IMIDAZOLIUM-5-OLATE
PT101007A (en) ICRF-187 lyophilized and stably prepared and its use and ICRF-187 lyophilized preparation process
SE8204693D0 (en) HEALTH SPECIALS WITH ANTIARRHYTHMIC AND SUBSIDIARY EFFECTS IN HYPOXIE DES MYOCARDS AND ITS RECOVERY PROCEDURES
RU93036929A (en) METHOD OF CLEANING GADOLINIA-153 PREPARATION FROM EUROPY-152
GB866423A (en) Improvements in or relating to chymotrypsin solutions
RU97112901A (en) THROMBOLYTIC PRODUCTS
TH13627EX (en) Benzophosphorus derivatives and pharmaceutical mixtures
JPS5732225A (en) Human plasmatic crystalline alpha2-macroglobulin and its preparation
RU94001413A (en) Agent for decrease of pathological vessel permeability to proteins
ATE75949T1 (en) STABILIZING AGENT AND INJECTABLE COMPOSITION CONTAINING THESE AGENT.
RU93019277A (en) SOLUTION FOR THE PROTECTION AND TREATMENT OF DISEASES AND DAMAGE TO THE CORNICE VIZITON
SU1450438A1 (en) COMPOSITION FOR POLISHING MONOCRYSTALS
RU96113752A (en) PHARMACEUTICAL COMPOSITION
RU94011275A (en) LINEAR PEPTIDES, METHOD OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND METHOD OF ITS PREPARATION